Advanced search
Start date
Betweenand

Evaluation of potential of lycopene encapsulated chitosan nanoparticles associated with D-±-tocopheryl polyethylene glycol 1000 succinate functionalized with bevacizumab in the treatment of Prostate Cancer

Grant number: 20/06212-3
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): June 01, 2021
Effective date (End): March 31, 2024
Field of knowledge:Health Sciences - Pharmacy - Pharmaceutical Technology
Principal researcher:Marlus Chorilli
Grantee:Jennifer Thayanne Cavalcante de Araújo
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Prostate Cancer is the second cancer with the highest mortality in Brazil, affecting mainly men in old age. The recommended treatment varies according to the tumor stage, and it is possible to choose therapies alone or in combination. Among therapies, chemotherapeutic agents are widely used; however, the tumor may show resistance causing the efflux of drugs from the cell, in addition to generating numerous side effects because it also affects healthy cells. Substances of natural origin, such as lycopene, the carotenoid responsible for the red pigmentation of tomatoes (Solanum lycopersicum), have shown antiangiogenesis and antitumor action in in vitro tests of Prostate Cancer strains. However, lycopene is highly hydrophobic and has low bioavailability, and its incorporation in drug delivery systems based on nanotechnology, such as chitosan nanoparticles associated with D-±-tocopheryl polyethylene glycol 1000 (TPGS) succinate, which has gained space in cancer therapy, as they can encapsulate hydrophilic or hydrophobic substances, improve drug stability properties, help in the controlled release process, solubility in water, reduce toxicity, internalization and apoptosis of cancer cells. The nanoparticles can have their surface modified by the coupling of ligands or antibodies that assist in specific binding to the target cell, such as bevacizumab, an antiangiogenesis agent, a property that is associated with the invasive process of the tumor. Thus, the present work aims to encapsulate lycopene in chitosan nanoparticles associated with TPGS and functionalize them with bevacizumab for the treatment of Prostate Cancer. The nanoparticles developed will be physicochemically characterized, evaluated for functionalization efficiency, encapsulation, lycopene release in vitro, cytotoxicity in vitro against prostate tumor cell lines (PC-3 and DU145) and in vivo antitumor activity. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DE ARAUJO, JENNIFER THAYANNE CAVALCANTE; TAVARES JUNIOR, ALBERTO GOMES; DI FILIPPO, LEONARDO DELELLO; DUARTE, JONATAS LOBATO; RIBEIRO, TAIS DE CASSIA; CHORILLI, MARLUS. Overview of chitosan-based nanosystems for prostate cancer therapy. EUROPEAN POLYMER JOURNAL, v. 160, . (19/19228-8, 19/25125-7, 18/18488-3, 20/06212-3)
CARVALHO, GABRIELA CORREA; FURQUIM DE CAMARGO, BRUNA ALMEIDA; CAVALCANTE DE ARAUJO, JENNIFER THAYANNE; CHORILLI, MARLUS. Lycopene: From tomato to its nutraceutical use and its association with nanotechnology. TRENDS IN FOOD SCIENCE & TECHNOLOGY, v. 118, p. 447-458, . (19/26821-7, 20/06212-3)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.